{"id":"zynrelef","rwe":[],"tags":[],"safety":{"boxedWarnings":["WARNING: RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS WARNING: RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS See full prescribing information for complete boxed warning. Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use ( 5.1 ) ZYNRELEF is contraindicated in the sett"],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[{"effect":"Vomiting","drugRate":"","severity":"common","organSystem":""},{"effect":"Constipation","drugRate":"","severity":"common","organSystem":""},{"effect":"Headache","drugRate":"","severity":"common","organSystem":""},{"effect":"Pruritus","drugRate":"","severity":"common","organSystem":""},{"effect":"Postoperative anemia","drugRate":"","severity":"common","organSystem":""}],"contraindications":[],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[{"effect":"Peptic ulcer hemorrhage","drugRate":"","severity":"serious"},{"effect":"Gastritis requiring hospitalization","drugRate":"","severity":"serious"},{"effect":"Hematemesis","drugRate":"","severity":"serious"},{"effect":"Melena","drugRate":"","severity":"serious"},{"effect":"Gastrointestinal hemorrhage","drugRate":"","severity":"serious"},{"effect":"Increased hepatic enzymes","drugRate":"","severity":"serious"}]},"trials":[],"_chembl":{"chemblId":"CHEMBL1098","moleculeType":"Small molecule","molecularWeight":"288.44"},"aliases":[],"patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=Zynrelef","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T01:30:59.224043+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-20T01:31:12.689374+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T01:31:04.696565+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Zynrelef","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T01:31:05.162116+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Sodium channel protein type IV alpha subunit blocker","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:31:06.295231+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1098/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:31:05.962538+00:00"}},"offLabel":[],"timeline":[],"_dailymed":{"setId":"dab484a7-9353-43ba-9e74-7fab910c712b","title":"ZYNRELEF (BUPIVACAINE AND MELOXICAM) SOLUTION [HERON THERAPEUTICS, INC.]"},"aiSummary":"Zynrelef is a marketed drug developed by Texas Tech University Health Sciences Center, currently holding a position in the pain management market. The key composition patent for Zynrelef is set to expire in 2028, providing a period of exclusivity that supports its market presence. The primary risk facing Zynrelef is the potential increase in competition following the patent expiry in 2028.","ecosystem":[],"mechanism":{},"_scrapedAt":"2026-03-28T00:16:51.911Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"references":[],"_validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T01:31:12.689508+00:00","fieldsConflicting":0,"overallConfidence":0.95},"biosimilars":[],"competitors":[],"dataSources":[],"indications":{"approved":[],"offLabel":[],"pipeline":[]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT07430085","phase":"PHASE4","title":"Post-Operative Pain Relief: Zynrelef or Periarticular Injections in RATKA","status":"NOT_YET_RECRUITING","sponsor":"Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)","startDate":"2026-01-31","conditions":"Periarticular Block, Osteoarthritis (OA), Osteoarthritis (OA) of the Knee","enrollment":150},{"nctId":"NCT07280195","phase":"PHASE4","title":"ZYNRELEF vs Continuous Catheter for Pain Management Following Shoulder Arthroplasty","status":"ENROLLING_BY_INVITATION","sponsor":"Washington University School of Medicine","startDate":"2026-02-14","conditions":"Total Shoulder Arthroplasty, Pain Management","enrollment":86},{"nctId":"NCT07216586","phase":"PHASE4","title":"Zynrelef Versus Adductor Canal Block","status":"NOT_YET_RECRUITING","sponsor":"University of Miami","startDate":"2026-06","conditions":"Knee Osteoarthritis, Arthritis Knee","enrollment":120},{"nctId":"NCT05188053","phase":"PHASE4","title":"Periarticular Bupivacaine + Meloxicam ER Solution Versus Standard Practice During Total Knee Arthroplasty","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2022-03-11","conditions":"Total Knee Arthroplasty","enrollment":209},{"nctId":"NCT05644496","phase":"PHASE4","title":"ZYNRELEF for Pain Management in Total Knee Arthroplasty","status":"RECRUITING","sponsor":"Baptist Health South Florida","startDate":"2023-03-09","conditions":"Post Operative Pain, Osteoarthritis, Knee","enrollment":242},{"nctId":"NCT06349772","phase":"EARLY_PHASE1","title":"Zynrelef vs Exparel: The Battle of Postoperative Pain Control After Robotic Sleeve Gastrectomy","status":"RECRUITING","sponsor":"Texas Tech University Health Sciences Center","startDate":"2024-11-01","conditions":"Post Operative Pain","enrollment":130},{"nctId":"NCT06109415","phase":"PHASE4","title":"A Multi-surgery Assessment of ZYNRELEF (HTX-011), AMAZE.","status":"COMPLETED","sponsor":"Heron Therapeutics","startDate":"2021-10-20","conditions":"Postoperative Pain, Total Shoulder Arthroplasty, Multimodal Analgesia","enrollment":30},{"nctId":"NCT06109428","phase":"PHASE4","title":"A Multi-surgery Assessment of ZYNRELEF (HTX-011), AMAZE","status":"COMPLETED","sponsor":"Heron Therapeutics","startDate":"2021-10-12","conditions":"Analgesia","enrollment":30},{"nctId":"NCT05109312","phase":"PHASE4","title":"A Multi-surgery Assessment of ZYNRELEF (HTX-011), AMAZE. Master Protocol HTX-011-401.","status":"UNKNOWN","sponsor":"Heron Therapeutics","startDate":"2021-10-12","conditions":"Analgesia","enrollment":90},{"nctId":"NCT05863221","phase":"PHASE4","title":"ZYNRELEF® for Postoperative Analgesia After Laparoscopic Sleeve Gastrectomy","status":"UNKNOWN","sponsor":"Dr. Yannis Raftopoulos","startDate":"2023-05-09","conditions":"Post Operative Pain, Acute, Bariatric Surgery Candidate, Postoperative Pain","enrollment":120},{"nctId":"NCT05751421","phase":"PHASE3","title":"Pain Relief After PrimaryTKA","status":"UNKNOWN","sponsor":"Rothman Institute Orthopaedics","startDate":"2023-02-28","conditions":"Pain, Postoperative","enrollment":60}],"_emaApprovals":[],"_faersSignals":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"crossReferences":{"chemblId":"CHEMBL1098"},"formularyStatus":[],"_approvalHistory":[{"date":"20240123","type":"SUPPL","sponsor":"HERON THERAPS INC","applicationNumber":"NDA211988"},{"date":"20211208","type":"SUPPL","sponsor":"HERON THERAPS INC","applicationNumber":"NDA211988"},{"date":"20210512","type":"ORIG","sponsor":"HERON THERAPS INC","applicationNumber":"NDA211988"},{"date":"20241121","type":"SUPPL","sponsor":"HERON THERAPS INC","applicationNumber":"NDA211988"},{"date":"20240924","type":"SUPPL","sponsor":"HERON THERAPS INC","applicationNumber":"NDA211988"},{"date":"20221213","type":"SUPPL","sponsor":"HERON THERAPS INC","applicationNumber":"NDA211988"}],"developmentCodes":[],"ownershipHistory":[],"publicationCount":14,"therapeuticAreas":["Other"],"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturerList":[],"phase":"marketed","status":"active","brandName":"Zynrelef","genericName":"Zynrelef","companyName":"Texas Tech University Health Sciences Center","companyId":"texas-tech-university-health-sciences-center","modality":"Small molecule","firstApprovalDate":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T01:31:12.689508+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":false,"safety":true,"trials":true,"score":2}}